B2 型胸腺瘤的治疗与预后。
Treatment and prognosis of type B2 thymoma.
机构信息
Department of Chemotherapy, Zhejiang Cancer Hospital, 38 Guangji Road, Hangzhou 310022, China.
出版信息
World J Surg Oncol. 2014 Sep 20;12:291. doi: 10.1186/1477-7819-12-291.
BACKGROUND
Because of the rarity of thymoma, no randomized trials have prospectively detected the prognosis and optimal treatment for type B2 thymoma. The aim of this study is to investigate the treatment and prognosis for patients with type B2 thymoma.
METHODS
We retrospectively evaluated the outcome of 42 patients with type B2 thymoma who were treated between 1995 and 2010 in Zhejiang Cancer Hospital. Survival curves were plotted using the Kaplan-Meier method. The Cox proportional hazard model was used for multivariate analysis.
RESULTS
The current study included 42 patients. The 5-year disease-free survival and overall survival rates were 62.8% and 84.9%, respectively. There were significant differences in disease-free survival and overall survival among different Masaoka stages (both P<0.001). Univariate and multivariate analysis revealed that Masaoka stage was associated with disease-free survival and overall survival (P=0.00 and 0.001, respectively).
CONCLUSIONS
Our results indicate that Masaoka stage affects disease-free survival and overall survival of patients with type B2 thymoma.
背景
由于胸腺瘤的罕见性，没有前瞻性随机试验检测 B2 型胸腺瘤的预后和最佳治疗方法。本研究旨在探讨 B2 型胸腺瘤患者的治疗和预后。
方法
我们回顾性评估了 1995 年至 2010 年间在浙江省肿瘤医院治疗的 42 例 B2 型胸腺瘤患者的结果。采用 Kaplan-Meier 法绘制生存曲线。采用 Cox 比例风险模型进行多因素分析。
结果
本研究共纳入 42 例患者。5 年无病生存率和总生存率分别为 62.8%和 84.9%。不同 Masaoka 分期的无病生存率和总生存率差异有统计学意义（均 P<0.001）。单因素和多因素分析显示，Masaoka 分期与无病生存率和总生存率相关（P=0.00 和 0.001）。
结论
我们的结果表明，Masaoka 分期影响 B2 型胸腺瘤患者的无病生存率和总生存率。
Zotero 插件